Xanodyne Pharmaceuticals
Pharmaceuticals, 1 Riverfront Pl Ste 900, Newport, Kentucky, 41071, United States, 51-200 Employees
Phone Number: +19*********
Who is XANODYNE PHARMACEUTICALS
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain...
Read More
-
Headquarters: 1 Riverfront Pl Ste 900, Newport, Kentucky, 41071, United States
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
Industry: Pharmaceuticals
SIC Code: 5122
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from XANODYNE PHARMACEUTICALS
Xanodyne Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Xanodyne Pharmaceuticals
Answer: Xanodyne Pharmaceuticals's headquarters are located at 1 Riverfront Pl Ste 900, Newport, Kentucky, 41071, United States
Answer: Xanodyne Pharmaceuticals's phone number is +19*********
Answer: Xanodyne Pharmaceuticals's official website is https://xanodyne.com
Answer: Xanodyne Pharmaceuticals's revenue is $50 Million to $100 Million
Answer: Xanodyne Pharmaceuticals's SIC: 5122
Answer: Xanodyne Pharmaceuticals's NAICS: 325412
Answer: Xanodyne Pharmaceuticals has 51-200 employees
Answer: Xanodyne Pharmaceuticals is in Pharmaceuticals
Answer: Xanodyne Pharmaceuticals contact info: Phone number: +19********* Website: https://xanodyne.com
Answer: Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas. We are developing: ZipsorTM for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month